

VETU (Derwent Veterinary Drug File)

Subject Coverage	All developments and applications of veterinary drugs: <ul style="list-style-type: none"> • Analysis • Biochemistry • Chemistry • Endocrinology • Management • Microbiology • Pathology • Pharmacology • Zoology 			
File Type	Bibliographic			
Features	Thesaurus	Controlled Term (/CT)		
	Alerts (SDIs)	Not available		
	CAS Registry Number® Identifiers	<input checked="" type="checkbox"/>	Page Images	<input type="checkbox"/>
	Keep & Share	<input checked="" type="checkbox"/>	SLART	<input type="checkbox"/>
	Learning Database	<input type="checkbox"/>	Structures	<input type="checkbox"/>
Record Content	<ul style="list-style-type: none"> • Bibliographic information, Derwent's abstract and extension abstracts, controlled term indexing and structure codes, as well as CAS Registry Numbers®, and Enzyme Commission Numbers, where applicable. 			
File Size	75,796 citations			
Coverage	1983-2001			
Updates	Closed file			
Language	English			
Database Producer	Clarivate Friars House, 160 Friars Rd. London SE1 8EZ United Kingdom Copyright Holder: Clarivate			

Sources • 1,100 veterinary and scientific journals and conference proceedings.

User Aids • Online Helps (HELP DIRECTORY lists all help messages available)
• STNGUIDE

Cluster • ALLBIB
• AUTHORS
• BIOSCIENCE
• CORPSOURCE
• TOXICOLOGY
STN Database Cluster information:
<https://www.cas.org/support/training/stn/database-clusters>

Related Databases VETB (data from 1968 to 1982)

Search and Display Field Codes

General Search Fields

Search Field Name	Search Code	Search Examples	Display Codes
Basic Index (contains single words from title (TI), controlled term (CT), abstract (AB) and extension abstract (ABEX), CAS Registry Numbers (RN), and Enzyme Commission Number (EC) fields)	None or /BI	S EFFECT# OF NALOXONE S FARM-ANIMAL(L)GONADOTROPIN-METAB? S 465-65-6 S EC-1.16.3.1	AB, ABEX, EC, CT, RN, TI
Accession Number	/AN	S 1993-61315/AN	AN
Author	/AU	S PARVIZI N/AU	AU
Availability of Document (1) (Reprint Address)	/AV	S INSTITUT TIERZUCHT NEUSTADT/AV	AV
CAS Registry Number	/RN	S 465-65-6/RN	CT, RN
Classification Code (1,2) (Profile Titles) (code and text)	/CC	S 10/CC S NON-STEROID HORMONES/CC	CC
Controlled Term (3,4) (limited by roles)	/CT	S MORPHINE-ANTAGONISTS/CT S MORPHINE-ANTAGONISTS *FT/CT(L) INJECTION *FT/CT	CT
Corporate Source (1)	/CS	S FDA DIV? SEAFOOD/CS	CS
Derwent Drug Registry Name (5) (link to file DRUGR)	/DDRN	S 1967U81/DDRN	CT
Document Type (code and text)	/DT (or /TC)	S JOURNAL/DT S J/DT	DT
Entry Date (6)	/ED (or /UP)	S L5 AND ED>19941020	not displayed
Enzyme Commission Number	/EC	S EC-1.16.3.1/EC	CT, EC
Field Availability	/FA	S L7 AND MPC/FA	FA
International Standard (Document) Number (CODEN)	/ISN	S JRPFA4/ISN	SO
Journal Title	/JT	S J REPROD FERTIL/JT	SO
Language (ISO code and text)	/LA	S L7 AND DE/LA S GERMAN/LA	LA
Location (1)	/LO	S (BASLE OR BASEL)/LO	LO
Multipunch Code (7) (limited by roles)	/MPC	S 076 080 104 254/MPC S 076 *G 080 *G 104 *G 254 *G/MPC	MPC
Publication Year (6)	/PY	S 1991-1993/PY	SO
Source (contains journal title, CODEN, collation)	/SO	S REPROD FERTIL/SO S JRPFA4/SO S FOOD CHEM/SO(L)32 NO 3/SO	SO
Subject Heading (8) (Thematic Groups) (code and text)	/SH	S G/SH S GALENICS/SH	SH
Title	/TI	S EFFECT OF NALOXONE/TI	TI

(1) Search with implied (S) proximity is available in this field.

(2) The 16 Profile Titles (/CC) were introduced in 1991.

(3) There are 9 roles available in field /CT to limit a search to a particular aspect of a drug or a disease: AE Adverse Effects, DI Drug Interactions, DM Drug Metabolism, FT Further Term (assigned when no other role assigned), OC Other Context, PH Pharmacology, RC Reference Compound, RN Registry Name, TR Treatment.

(4) Controlled terms concerning the same drug in a record are linked by (L) proximity.

(5) For file crossover to file DRUGR, SELECT DDRN and search the resulting E-number(s) in DRUGR.

(6) Numeric search field that may be searched using numeric operators or ranges.

(7) Search with implied (L) proximity is available in this field. Multipunch codes concerning the same drug in a record are linked by (L) proximity.

(8) The 15 Thematic Groups (/SH) were used prior to 1991.

The Derwent Veterinary Drug File Thesaurus

Field	Relationship code	Content	Examples
/CT	ALL	All Associated Terms (BT, SELF, USE, UF, SEE, NEW, OLD, TN, EC, CN, RT, NT, NTE, ONTE)	E DACARBAZINE+ALL/CT
	AUTO (1)	Automatic Relationship (SELF, USE, UF, SEE, NEW, OLD, TN, EC, CN, NT, ONTE)	S DETICENE+AUTO/CT
	BT	Broader Terms (BT, SELF, also BT1, BT2 etc. possible)	E DACARBAZINE+BT/CT
	HIE	Hierarchy (BT, SELF, NT)	E MITE+HIE/CT
	NT	Narrower Terms (SELF, NT, also NT1, NT2 etc. possible)	E MITE+NT/CT
	PFT	All Preferred and Forbidden Terms (SELF, USE, UF, SEE, SF, NEW, OLD, TN, EC, CN)	E DACARBAZINE+PFT/CT
	RT	Related Terms (SELF, RT)	E MINERALOCORTICOID+RT/CT
	TN	Trade Names (SELF, TN)	E DACARBAZINE+TN/CT
	UF	Preferred and Forbidden Terms (SELF, UF)	E DACARBAZINE+UF/CT
	USE	Forbidden and Preferred Terms (SELF, USE)	E DTIC+USE/CT

(1) Automatic Relationship is SET OFF. In case of SET REL ON the result of EXPAND or SEARCH without any relationship code is the same as described for AUTO.

DISPLAY and PRINT Formats

Any combination of formats may be used to display or print answers. Multiple codes must be separated by spaces or commas, e.g., D L1 1-5 TI CS. The fields are displayed or printed in the order requested.

Hit-term highlighting is available for all fields. Highlighting must be ON during SEARCH to use the HIT, KWIC, and OCC formats.

Format	Content	Examples
AB	Abstract	D TI AB 1-4
ABEX	Abstract Extension	D ABEX
AN	Accession Number	DIS AN
AU	Author	D AU TI 1-10
AV	Availability of Document (Reprint Address)	D TI AV 1-5
CC	Classification Code	D CC
CS	Corporate Source	D CS
CT	Controlled Term (incl. Enzyme Com. Nos. and CAS Registry Numbers)	D CT
DDRN	Derwent Drug Registry Name	D DCRN
DT (TC)	Document Type	D DT LA
EC	Enzyme Commission Number	D EC
FA	Field Availability	D AN FA
ISN (1)	International Standard (Document) Number	D JT ISN
JT (1)	Journal Title	D JT
LA	Language	D LA
LO	Location	D CS LO
MPC	Multipunch Code	D MPC
PY (1)	Publication Year	D PY
RN (1)	CAS Registry Number	D RN
SH	Subject Heading	D SH
SO	Source	D SO
TI	Title	D TI 5

DISPLAY and PRINT Formats (cont'd)

Format	Content	Examples
ABS ALL IALL BIB CBIB IBIB IND MAX TRIAL (TRI, SAM)	AN, AB, ABEX AN, TI, AU, CS, LO, SO, AV, LA, DT, AB, SH, CC, CT, FA ALL, indented with text labels AN, TI, AU, CS, LO, SO, AV, LA, DT, FA AN, TI, AU, CS, LO, SO, AV, LA, DT (compressed bibliography) BIB, indented with text labels AN, SH, CC, CT, MPC AN, TI, AU, CS, LO, SO, AV, LA, DT, AB, ABEX, SH, CC, CT, MPC, FA AN, TI, CC, CT	D ABS D ALL D IALL D BIB D CBIB D IBIB D IND D MAX D TRIAL
HIT KWIC OCC	Hit term(s) and field(s) Up to 50 words before and after hit term(s) (KeyWord-In-Context) Number of occurrences of hit term(s) and field(s) in which they occur	D HIT D KWIC D OCC

(1) Custom display only.

SELECT, ANALYZE, and SORT Fields

The SELECT command is used to create E-numbers containing terms taken from the specified field in an answer set.

The ANALYZE command is used to create an L-number containing terms taken from the specified field in an answer set.

The SORT command is used to rearrange the search results in either alphabetic or numeric order of the specified field(s).

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Abstract	AB	Y (2)	N
Abstract Extension	ABEX	Y (2)	N
Accession Number	AN	Y	N
Author	AU	Y	Y
Availability of Document	AY	Y	Y
CAS Registry Number	RN	Y	N
Citation	CIT (RE)	Y	N
Classification Code	CC	Y	Y
CODEN	CODEN	N	Y
Controlled Term	CT	Y	N
Corporate Source	CS	Y	Y
Derwent Crop Registry Name	DDRN	Y	N
Document Type	DT (TC)	Y	Y
Enzyme Commission Number	EC	Y	Y
Field Availability	FA	Y	Y
International Standard (Document) Number	ISN	Y (3)	N
Journal Title	JT	Y	Y
Language	LA	Y	Y
Location	LO	Y	Y
Multipunch Code	MPC	Y	N
Occurrence Count of Hit Terms	OCC	N	Y
Publication Year	PY	Y	Y
Source	SO	Y (4)	N
Subject Heading	SH	Y	Y
Title	TI	Y (default)	Y

(1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HIT TI.

(2) Appends /BI to the terms created by SELECT.

(3) Selects or analyzes CODEN and appends /ISN to the terms created by SELECT.

(4) Selects or analyzes CODEN and appends /SO to the terms created by SELECT.

Sample Records

DISPLAY MAX

AN 2001-63368 VETU
TI In vivo effect of a COX-2 selective and nonselective nonsteroidal anti-inflammatory drug on gastric mucosal and synovial fluid prostaglandin synthesis in dogs.
AU Jones C J; Streppa H K; Budsberg S C
CS Univ.Georgia
LO Athens, Ga., USA
SO Vet.Surg. (30, Number 5, 497, 2001)
AV University of Georgia, Athens, GA, U.S.A.
LA English
DT Journal
AB The in-vivo activity of a known selective COX-2 inhibitor, meloxicam (MX), and a nonselective NSAID, aspirin (AS), on the gastric mucosa and synovial fluid of dogs with osteoarthritis was investigated, and this activity was correlated with COX-1 and COX-2 inhibition in blood. The results showed that LPS-stimulated PGE2 in blood and PGE2 in synovial fluid were suppressed by both AS and MX, which is consistent with activity against the COX-2 isoenzyme. AS, but not MX, suppressed PGE2 in the gastric mucosa and TXB2 in blood, which is consistent with activity against COX-1. This in-vivo model confirms a beneficial effect of a COX-2 selective inhibitor, MX, on PG inhibition in the synovial fluid, while sparing gastric mucosal PG synthesis. (conference abstract: American College of Veterinary Surgeons, 11th Annual Symposium, Chicago, Illinois, USA, October, 2001).

ABEX 12 Dogs with unilateral osteoarthritis of the stifle were treated in a crossover design with AS or MX for 21 days with a 6-mth washout between treatments. PGE2 levels in LPS-stimulated whole blood, synovial fluid, and endoscope gastric mucosal biopsies, and thromboxane B2 (TXB2) in serum were measured on days 0, 7 and 21 of each treatment period using ELISA. AS significantly suppressed PGE2 in blood, gastric mucosa and synovial fluid, as well as TXB2 in serum on days 7 and 21. MX significantly suppressed PGE2 in blood and synovial fluid on days 7 and 21 but had no effect on TXB2 in serum or PGE2 in gastric mucosa. (CLW)

CC 1 Anesthesia and Pharmacology
CT OSTEOARTHRITIS *OC; JOINT-DISEASE *OC; IN-VIVO *FT; DOG *FT; GASTRIC *FT; MUCOSA *FT; SYNOVIAL *FT; FLUID *FT; PGE2 *FT; PROSTAGLANDIN-METAB. *FT; PROSTAGLANDIN-ANTAGONIST *FT; THROMBOXANE-ANTAGONIST *FT; ANTIINFLAMMATORY *FT; SMALL-ANIMAL *FT
[01] ASPIRIN *PH; ASPIRIN *RN; CYCLOOXYGENASE-1-INHIBITOR *FT; CYCLOOXYGENASE-INHIBITOR *FT; PROSTAGLANDIN-ANTAGONIST *FT; ANALGESICS *FT; ANTIPYRETICS *FT; ANTIRHEUMATICS *FT; ANTIAGGREGANTS *FT; ANTIINFLAMMATORIES *FT; PH *FT
[02] MELOXICAM *PH; MELOXICAM *RN; CYCLOOXYGENASE-2-INHIBITOR *FT; CYCLOOXYGENASE-INHIBITOR *FT; PROSTAGLANDIN-ANTAGONIST *FT; ANTIINFLAMMATORIES *FT; CYCLOOXYGENASE-INHIBITORS *FT; CYCLOOXYGENASE-2-INHIBITORS *FT; PH *FT

FA AB; LA; CT

In North America
CAS Customer Center:
P.O. Box 3012
Columbus, Ohio 43210-0012
U.S.A.

Phone: 800-753-4227 (North America)
614-447-3731 (worldwide)
E-mail: help@cas.org
Internet: www.cas.org

In Europe
CAS Customer Center EMEA
(represented by FIZ Karlsruhe)
P.O. Box 2465
76012 Karlsruhe
Germany

Phone: +49-7247-808-555
E-mail: EMEAhelp@cas.org
Internet: www.stn-international.com

In Japan
JAICI (Japan Association for
International Chemical Information)
Nakai Building
6-25-4 Honkomagome, Bunkyo-ku
Tokyo 113-0021
Japan

Phone: +81-3-5978-3601 (Technical Service)
+81-3-5978-3621 (Customer Service)
E-mail: support@jaici.or.jp (Technical Service)
customer@jaici.or.jp (Customer Service)
Internet: www.jaici.or.jp